Assessing rheumatoid arthritis patients' blood levels of the human 14-3-3 protein antibodies

Rheumatoid arthritis (RA) sufferers may have several problems. Common and significant complications, particularly in rheumatoid arthritis (RA), include synovitis, joint deformity, and structural bone loss. This study aimed to compare the biomarker 14-3-3 protein in patients with rheumatoid arthritis and a healthy group. Female patients were collected from rheumatoid arthritis clinics in Karbala city. Blood samples were taken from 50 healthy women as a control group and 80 patients with RF disease. Information about patients and samples was collected, and Statistical analysis showed that the amount of 14-3-3 protein in rheumatoid arthritis patients was significantly higher (p < 0.001) than in the control group. There was also a significant increase (p < 0.001) in the amount of 14-3-3 protein, based on age and whether before or after menopause, compared to individuals with rheumatoid arthritis in the control group. Statistical analysis revealed that the new diagnostic group's blood level of human 14-3-3 eta protein (16.74 ± 0.30 ng/ml) was considerably greater (p < 0.005) than that of the treated group. Furthermore, a statistically significant (p<0.001) rise in the human 14-3-3 serum level was observed in the group that was obese as opposed to the groups that were overweight and normal weight, respectively. Furthermore, the 1-year-old group's blood level of human 14-3-3 eta protein was statistically significantly (p<0.001) higher than that of the 1–10 and 11–19-year-old groups, respectively. Also, serum human 14-3-3 eta protein was positively correlated with RF and ACPAs and negatively correlated with estradiol-17b in women with RA.